Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Qutiro
In five patients after infusion of the product, chills and chest pain occurred and blood cultures grew Klebsiella pneumoniae ESBL; in another three patients, chills progressed to generalized convulsions. A real threat to patients’ health or life was indicated. Potential effects: severe bloodstream infection, septic complications, life‑threatening condition.
Qutiro
In patients after infusion of the product, chills, chest pain and generalized convulsions occurred; blood cultures grew Klebsiella pneumoniae ESBL, and the inspector indicated a real threat to patients’ health or life. Potential effects: severe bloodstream infections, septic shock, life‑threatening conditions.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content in reference samples of several batches and a failure in the capsule mass uniformity parameter, caused among others by loss of active substance during filling and lack of full capsule weight control. Potential effects: reduced treatment effectiveness, possible worsening of disease symptoms.
Konaten
In reference samples, out-of-specification (OOS) results were found for atomoxetine content, and for batch 1304011 also for capsule mass uniformity, which may affect dosing. Potential effects: reduced treatment efficacy or adverse reactions due to incorrect dose.
Konaten
Out-of-specification (OOS) results were found in retention samples for atomoxetine content and, for batch 1304011, also for mass uniformity; the impact of this non‑conformity on the drug’s efficacy and safety cannot be determined. Potential effects: reduced treatment efficacy or unpredictable adverse effects.
Paracetamol Aflofarm
Tests showed that despite shaking, sediment remains at the bottom of the bottle and some doses contain paracetamol outside the specification (e.g. 141.2 mg/5 ml with a limit of 114.0–126.0 mg/5 ml). Potential effects: risk of paracetamol overdose or incorrect treatment efficacy.
Palifren Long
A justified suspicion of a quality defect of the medicinal product was identified, and its occurrence was subsequently confirmed in batches 4201120, 4300099 and 4201591. The nature of the defect is not specified in the decision. Potential effects: possible treatment complications, lack of efficacy or adverse reactions.
Konaten
Out-of-specification results were found for atomoxetine content in seven batches and non-compliance in the mass uniformity parameter in batch 1311190, posing a real and direct risk to patients' health or life. Potential effects: reduced treatment efficacy, unstable drug effect, possible worsening of disease symptoms.
Egoropal
An out-of-specification result for the particle size parameter was found due to an incorrect limit at a manufacturing process stage (IPC), constituting a quality defect in batch 4201475. Potential effects: altered drug release, risk of lack of efficacy or increased adverse effects.
Konaten
Testing of reference samples showed that the batches covered by the decision do not meet specifications for atomoxetine content, and batch 1311190 also fails the mass uniformity parameter. Potential effects: reduced treatment efficacy, variable dosing, possible therapy complications.
Konaten
Tests of reference samples showed that the batches covered by the decision do not meet the requirements for atomoxetine content, and batch 1311190 also fails the uniformity of mass parameter, which poses a real and direct risk to patients’ health. Potential effects: reduced treatment efficacy, risk of symptom worsening, possible complications resulting from improper dosing.
Konaten
In testing of reference samples from several batches, results outside the quality specification were found for atomoxetine content and, for one batch, non-compliance in mass uniformity, which constitutes a real and direct risk to patients’ health or life. Potential effects: reduced treatment efficacy, possible worsening of disease symptom control.
Corhydron 25
Stability studies showed that the batch does not meet quality requirements (result above the limit for free hydrocortisone content), which according to the authority constitutes a real and direct threat to patients’ health or life. Potential effects: impaired treatment efficacy, unpredictable adverse reactions, complications.
Palifren Long
The National Medicines Institute found that the product did not meet quality requirements due to a negative test result for the parameters: paliperidone palmitate content and particle size analysis. Potential effects: impaired treatment effectiveness, adverse effects, complications.
Palifren Long
This product does not meet the specified quality requirements due to a negative test result for paliperidone palmitate content and particle size analysis. Potential effects: lack of therapeutic efficacy or adverse reactions after parenteral administration.
Viglita
The product does not meet quality requirements due to an out-of-specification result for friability of uncoated tablets; the sample contained crushed, cracked or broken tablets. Potential effects: possible uneven dosing of the drug and reduced therapeutic efficacy.
Oekolp forte
An exceedance of the acceptable content of an unknown impurity was found in batch 23000333, making it impossible to assess the safety of the medicine’s use; the authority indicated a real risk to patients’ health and potentially life. Potencjalne skutki: poisoning, unknown adverse reactions, threat to health or life.
Oekolp forte
Exceeding the established limit of an unknown impurity was found in batch 23000333, making it impossible to assess safety of use. The authority indicated a real risk to patients’ health and potentially life. Potential effects: poisoning, serious adverse reactions, life‑threatening events.
Reparil Gel N
The application explained that the manufacturer is preparing documentation on the root cause of the non-conformity, implemented corrective and preventive actions, and identified violations of the product’s quality requirements. Potential effects: possible reduced treatment effectiveness or occurrence of unexpected adverse reactions.
Egoropal
It was found that the product does not meet quality requirements due to a failed particle size analysis in the injectable suspension. Potential effects: possible altered drug release, lack of efficacy or unpredictable adverse reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.